National Taiwan University Hospital NTUH

Taipei 10002

1 studies enrolling now · 13 studies all time

What they study most

Adult Acute Myeloid Leukemia, Advanced or Metastatic NSCLC, EGFR Exon 19 Deletion, EGFR L858R, Follicular Lymphoma (FL), Gastro-Oesophageal Cancer, HER2-Positive Primary Breast Cancer, Immunoglobulin A Nephropathy, Marginal Zone Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Non Hodgkin Lymphoma, Non-Small Cell Lung Cancer Metastatic

Studies at this site

• Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT — Recruiting now
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer — Running, not enrolling
• RegoNivo vs Standard of Care Chemotherapy in AGOC — Completed
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) — Completed
• HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy — Running, not enrolling
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) — Stopped early
• A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer — Status unconfirmed
• Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study — Status unconfirmed